Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPYVLP01
- Development stage
- Phase 1
- Lead developer
- SpyBiotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SPYVLP01 is an investigational prophylactic vaccine candidate developed by SpyBiotech for the prevention of human cytomegalovirus (HCMV) infection. It utilizes a Hepatitis B virus-like particle (VLP) platform, leveraging SpyBiotech’s proprietary protein ‘superglue’ technology (SpyTag/SpyCatcher), which enables stable and efficient antigen display on the VLP surface to enhance immunogenicity. The vaccine is designed to stimulate an immune response against HCMV, a common betaherpesvirus that can cause lifelong infection and is a leading infectious cause of congenital abnormalities in newborns. There are currently no approved vaccines for HCMV. As of July 2024, SPYVLP01 has completed enrollment in a Phase I clinical trial evaluating its safety and immunogenicity in healthy adults aged 18–50 years[3][5][6][8].
- Other names
- CMV pentamer-HBsAg VLP vaccineHepatitis B surface antigen virus-like particle cytomegalovirus vaccinepentamer-hepatitis B surface antigen virus-like particle cytomegalovirus vaccine
Beyond the preview
Go deeper on SPYVLP01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPYVLP01.